BNB Treasury Firm Windtree Plunges 77% as Nasdaq Moves to Delist Over Compliance Failure
Windtree Therapeutics noticed its shares collapse on Wednesday after Nasdaq mentioned it could delist the biotech for failing to adjust to itemizing requirements. Key Takeaways: Windtree Therapeutics’ inventory collapsed 77% after Nasdaq moved to delist the biotech for failing to fulfill the $1 minimal bid value rule. The corporate had just lately launched a BNB…
